Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | PREP | P48147 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13099500 | 1.00 | MEN1 (0.67) | MEN1KMT2APREPALDH1A1HCRTR1 | |
| SCHEMBL13108659 | 1.00 | MEN1 (0.67) | MEN1KMT2APREPALDH1A1HCRTR1 | |
| SCHEMBL3263076 | 0.94 | KMT2A (0.60) | MEN1KMT2APREPALDH1A1HCRTR1 | |
| SCHEMBL13099504 | 0.94 | KMT2A (0.60) | MEN1KMT2APREPALDH1A1HCRTR1 | |
| SCHEMBL13108431 | 0.94 | KMT2A (0.60) | MEN1KMT2APREPALDH1A1HCRTR1 | |
| SCHEMBL13099487 | 0.81 | MEN1 (1.00) | MEN1KMT2APREPALDH1A1HCRTR1 | |
| SCHEMBL13108664 | 0.81 | MEN1 (1.00) | MEN1KMT2APREPALDH1A1HCRTR1 | |
| SCHEMBL13099498 | 0.78 | PREP (0.45) | MEN1KMT2APREPALDH1A1HCRTR1 | |
| SCHEMBL13108591 | 0.78 | PREP (0.45) | MEN1KMT2APREPALDH1A1HCRTR1 | |
| SCHEMBL13099509 | 0.77 | PREP (0.68) | MEN1KMT2APREPALDH1A1HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243333-A1 | SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS | UNIVERSITY OF KANSAS (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243333-A1 | SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS | OPRM1, OPRK1, OPRD1 | MEN1 3913/4885KMT2A 1523/4885PREP 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.